BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee CY. Glucagon-Like Peptide-1 Formulation--the Present and Future Development in Diabetes Treatment. Basic Clin Pharmacol Toxicol 2016;118:173-80. [PMID: 26551045 DOI: 10.1111/bcpt.12524] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Liu C, Guo Z, Yang Y, Hu B, Zhu L, Li M, Gu Z, Xin Y, Sun H, Guan Y, Zhang L. Identification of dipeptidyl peptidase-IV inhibitory peptides from yak bone collagen by in silico and in vitro analysis. Eur Food Res Technol. [DOI: 10.1007/s00217-022-04111-x] [Reference Citation Analysis]
2 Ibnat N, Zaman R, Uddin MB, Chowdhury E, Lee CY. Improved systemic half-life of glucagon-like peptide-1-loaded carbonate apatite nanoparticles in rats. World J Diabetes 2022; 13(8): 613-621 [DOI: 10.4239/wjd.v13.i8.613] [Reference Citation Analysis]
3 Lee CY. A Combination of Glucagon-Like Peptide-1 Receptor Agonist and Dietary Intervention Could Be a Promising Approach for Obesity Treatment. Front Endocrinol (Lausanne) 2021;12:748477. [PMID: 34616367 DOI: 10.3389/fendo.2021.748477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yang Y, Shi CY, Xie J, Dai JH, He SL, Tian Y. Identification of Potential Dipeptidyl Peptidase (DPP)-IV Inhibitors among Moringa oleifera Phytochemicals by Virtual Screening, Molecular Docking Analysis, ADME/T-Based Prediction, and In Vitro Analyses. Molecules 2020;25:E189. [PMID: 31906524 DOI: 10.3390/molecules25010189] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
5 Kartinah NT, Fadilah F, Ibrahim EI, Suryati Y. The Potential of Hibiscus sabdariffa Linn in Inducing Glucagon-Like Peptide-1 via SGLT-1 and GLPR in DM Rats. Biomed Res Int 2019;2019:8724824. [PMID: 31828140 DOI: 10.1155/2019/8724824] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Vass P, Démuth B, Hirsch E, Nagy B, Andersen SK, Vigh T, Verreck G, Csontos I, Nagy ZK, Marosi G. Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals. J Control Release 2019;296:162-78. [PMID: 30677436 DOI: 10.1016/j.jconrel.2019.01.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
7 Gupta RC, Lall R, Sinha A, Srivastava A. Nutraceuticals for Diabetes in Dogs and Cats. Nutraceuticals in Veterinary Medicine 2019. [DOI: 10.1007/978-3-030-04624-8_35] [Reference Citation Analysis]
8 Evers A, Bossart M, Pfeiffer-marek S, Elvert R, Schreuder H, Kurz M, Stengelin S, Lorenz M, Herling A, Konkar A, Lukasczyk U, Pfenninger A, Lorenz K, Haack T, Kadereit D, Wagner M. Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations. J Med Chem 2018;61:5580-93. [DOI: 10.1021/acs.jmedchem.8b00292] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
9 Omotuyi OI, Nash O, Inyang OK, Ogidigo J, Enejoh O, Okpalefe O, Hamada T. Flavonoid-rich extract of Chromolaena odorata modulate circulating GLP-1 in Wistar rats: computational evaluation of TGR5 involvement. 3 Biotech 2018;8:124. [PMID: 29450114 DOI: 10.1007/s13205-018-1138-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
10 Wan Y, Bao X, Huang J, Zhang X, Liu W, Cui Q, Jiang D, Wang Z, Liu R, Wang Q. Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice. Front Physiol 2017;8:294. [PMID: 28555111 DOI: 10.3389/fphys.2017.00294] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]